Floyd Healthcare Management INC

Floyd Healthcare Management INC was paid $98.41M by Medicaid between Jan 2018 and Dec 2024, across 484 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.

33Billing provider infoFLOYD HEALTHCARE MANAGEMENT INC
ROME, GA 30161

33aNPI1356444814assigned 09/07/2006

33bProvider typeAmbulance

28Total paid$98.41M

24GClaims2,125,324

24DCodes billed484

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Ambulance providers in Georgia

Rank by total paid#1 of 10

Median peer was paid$6K

This provider vs. median15,909×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	342,437	$13.43M
2019	362,556	$13.63M
2020	288,999	$10.95M
2021	291,738	$12.91M
2022	269,350	$14.55M
2023	300,873	$16.06M
2024incomplete	269,371	$16.88M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	13%	48,483	42,832	$12.91M
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	12%	41,700	34,922	$11.70M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	9.7%	47,275	42,342	$9.54M
74177	Computed tomography, abdomen and pelvis; with contrast material	5.1%	9,821	9,075	$5.02M
96361	Intravenous infusion, hydration; each additional hour	4.0%	34,088	19,412	$3.90M
0202U	Oncology (prostate), multianalyte, gene expression profiling	3.8%	14,831	14,040	$3.70M
G0378	Hospital observation service, per hour	2.7%	37,511	14,089	$2.64M
A0427	Emergency ambulance ride, advanced life supportAmbulance service, advanced life support, emergency transport, level 1 (als 1 - emergency)	2.6%	21,567	15,285	$2.55M
69436	Tympanostomy (requiring insertion of ventilating tube), general anesthesia	2.5%	1,952	1,916	$2.49M
A0429	Emergency ambulance ride, basic life supportAmbulance service, basic life support, emergency transport (bls-emergency)	2.1%	18,586	13,497	$2.08M
70450	Computed tomography, head or brain; without contrast material	2.0%	11,358	10,215	$1.92M
71046	Radiologic examination, chest; 2 views	1.9%	19,963	18,221	$1.86M

472 more codes

D9420		1.8%	1,126	$1.81M
80053	Comprehensive metabolic panel	1.7%	100,827	$1.71M
74176	Computed tomography, abdomen and pelvis; without contrast material	1.3%	2,900	$1.28M
42820	Tonsillectomy and adenoidectomy; younger than age 12	1.3%	665	$1.23M
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.2%	109,665	$1.18M
G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.1%	26,046	$1.04M
71045	Radiologic examination, chest; single view	<1%	24,604	$946K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	32,913	$944K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	16,587	$807K
A0425	Ground mileage, per statute mile	<1%	46,121	$794K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	38,466	$777K
96375	Therapeutic injection; each additional sequential IV push	<1%	27,248	$676K
0240U		<1%	6,275	$651K
59025	Fetal non-stress test	<1%	10,513	$627K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	5,099	$614K
83880		<1%	26,709	$606K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	12,165	$600K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	16,776	$586K
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	<1%	34,517	$565K
72125	Computed tomography, cervical spine; without contrast material	<1%	3,570	$559K
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	<1%	34,984	$531K
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	<1%	3,348	$516K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	7,989	$504K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	3,024	$481K
99282	Emergency department visit for the evaluation and management, low to moderate severity	<1%	5,405	$436K
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	<1%	7,099	$430K
87081		<1%	36,232	$378K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	24,667	$362K
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	7,139	$344K
71275	Computed tomographic angiography, chest, with contrast material	<1%	2,338	$340K
76801		<1%	2,716	$329K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	2,236	$324K
84484		<1%	28,845	$313K
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	<1%	1,143	$307K
76642		<1%	2,482	$281K
81001		<1%	37,012	$273K
93458		<1%	800	$257K
87086	Culture, bacterial; quantitative colony count, urine	<1%	26,876	$251K
84443	Thyroid stimulating hormone (TSH)	<1%	19,525	$250K
74018		<1%	3,982	$246K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	5,068	$229K
96376		<1%	15,477	$222K
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	30,236	$219K
D0150	Comprehensive oral evaluation - new or established patient	<1%	569	$210K
80048	Basic metabolic panel (calcium, ionized)	<1%	31,063	$210K
81025		<1%	16,658	$208K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	834	$206K
47562		<1%	84	$200K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	4,380	$195K
83690		<1%	17,882	$192K
87040		<1%	10,958	$183K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	2,492	$182K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	12,199	$177K
93971		<1%	2,024	$174K
73630		<1%	2,520	$165K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	13,763	$163K
93041		<1%	16,353	$162K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	2,468	$156K
72110		<1%	1,537	$155K
99213	Doctor's office visit, returning patient (routine)	<1%	5,699	$154K
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	<1%	405	$153K
73610		<1%	2,291	$152K
73030		<1%	2,539	$148K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	3,284	$147K
74019		<1%	1,672	$145K
80061	Lipid panel	<1%	22,589	$140K
87430		<1%	7,364	$140K
86140		<1%	14,149	$139K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	3,056	$136K
90791	Psychiatric diagnostic evaluation	<1%	3,027	$130K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	621	$129K
73564		<1%	1,844	$128K
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	8,241	$126K
36592		<1%	10,496	$122K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	615	$121K
85730		<1%	24,728	$121K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	5,050	$117K
70486		<1%	814	$116K
93017		<1%	1,442	$114K
85610		<1%	34,829	$113K
D1208	Topical application of fluoride, excluding varnish	<1%	270	$111K
D1120	Dental cleaning, child	<1%	495	$110K
73130		<1%	1,736	$108K
73110		<1%	1,611	$105K
88304		<1%	2,609	$104K
84702		<1%	6,570	$102K
D2930	Prefabricated stainless steel crown - primary tooth	<1%	429	$100K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	888	$98K
85027		<1%	15,340	$96K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,936	$95K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	202	$93K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	117	$91K
96367		<1%	2,857	$90K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	916	$89K
A0428	Ambulance service, basic life support, non-emergency transport, (bls)	<1%	4,237	$87K
72100		<1%	1,373	$85K
83036	Hemoglobin; glycosylated (A1C)	<1%	13,570	$84K
87807		<1%	4,526	$83K
76830	Ultrasound, transvaginal	<1%	440	$82K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,934	$82K
93975		<1%	329	$82K
99214	Doctor's office visit, returning patient (more involved)	<1%	2,713	$79K
76942		<1%	900	$78K
87077		<1%	7,773	$76K
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	8,720	$74K
APT17		<1%	5,105	$73K
80320		<1%	6,286	$71K
87186		<1%	8,011	$70K
97597		<1%	2,409	$70K
73502		<1%	1,746	$70K
83605		<1%	8,318	$68K
86901		<1%	9,370	$68K
84703		<1%	5,301	$66K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	1,372	$66K
76770		<1%	612	$64K
81003		<1%	17,224	$63K
82607		<1%	5,825	$61K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	10,246	$61K
J7120	Ringers lactate infusion, up to 1000 cc	<1%	10,891	$60K
83735		<1%	14,146	$59K
99211	Office or other outpatient visit for the evaluation and management of an established patient, minimal severity	<1%	2,104	$59K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	9,020	$58K
86850		<1%	6,381	$58K
73590		<1%	978	$56K
93320		<1%	789	$55K
93325		<1%	918	$54K
72170		<1%	943	$54K
77066	Tomosynthesis, mammo	<1%	1,394	$54K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	2,773	$53K
82553		<1%	5,538	$53K
J7030	Infusion, normal saline solution , 1000 cc	<1%	15,157	$50K
80074		<1%	1,404	$50K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	578	$47K
97161		<1%	3,674	$47K
G0379	Direct admission of patient for hospital observation care	<1%	1,264	$46K
82728		<1%	4,587	$46K
73090		<1%	653	$46K
APT15		<1%	3,918	$45K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	18,084	$45K
85379		<1%	4,427	$43K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	5,676	$43K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	1,054	$42K
J2357	Injection, omalizumab, 5 mg	<1%	45	$41K
93351		<1%	213	$40K
74021		<1%	637	$39K
G0390	Trauma response team associated with hospital critical care service	<1%	38	$39K
D3220	Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction	<1%	155	$37K
84439		<1%	4,984	$37K
82803		<1%	3,057	$37K
82550		<1%	12,075	$36K
12001		<1%	343	$34K
S9443	Lactation classes, non-physician provider, per session	<1%	895	$34K
42830		<1%	24	$33K
77063	Screening digital breast tomosynthesis, bilateral	<1%	2,925	$33K
73080		<1%	556	$32K
APT16		<1%	2,223	$31K
99215	Doctor's office visit, returning patient (complex)	<1%	1,110	$31K
83718		<1%	2,595	$29K
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	11,760	$29K
87070		<1%	3,465	$29K
97010		<1%	7,217	$29K
82948		<1%	7,701	$28K
84145		<1%	1,647	$28K
86900		<1%	7,559	$28K
73562		<1%	803	$27K
80143		<1%	1,567	$26K
J2704	Injection, propofol, 10 mg	<1%	9,990	$26K
87631		<1%	335	$25K
97016		<1%	1,966	$24K
83550		<1%	3,715	$24K
80179		<1%	1,500	$24K
90715		<1%	1,328	$23K
J2785	Injection, regadenoson, 0.1 mg	<1%	388	$23K
36415	Collection of venous blood by venipuncture	<1%	72,617	$22K
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	12,767	$22K
J0690	Injection, cefazolin sodium, 500 mg	<1%	5,607	$21K
88307		<1%	270	$21K
36600		<1%	3,573	$21K
84146		<1%	1,040	$21K
83540		<1%	4,086	$20K
87088		<1%	2,587	$19K
76870		<1%	83	$19K
93880		<1%	264	$18K
12002		<1%	160	$18K
84112		<1%	379	$18K
85007		<1%	4,694	$17K
72050		<1%	212	$17K
84153		<1%	1,014	$16K
85652		<1%	4,011	$16K
88175	Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer	<1%	734	$15K
A0426	Ambulance service, advanced life support, non-emergency transport, level 1 (als 1)	<1%	352	$15K
82805		<1%	889	$15K
87205		<1%	3,552	$15K
J1170	Injection, hydromorphone, up to 4 mg	<1%	7,052	$15K
71101		<1%	227	$15K
82043		<1%	4,005	$15K
82746		<1%	1,862	$14K
80076		<1%	1,040	$14K
82150		<1%	1,698	$14K
51701		<1%	1,051	$14K
83970		<1%	575	$13K
80329		<1%	441	$13K
97014		<1%	2,009	$13K
76818		<1%	185	$13K
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	4,060	$13K
12011		<1%	150	$13K
76536		<1%	81	$12K
72141		<1%	89	$12K
93970		<1%	108	$12K
A9577	Injection, gadobenate dimeglumine (multihance), per ml	<1%	615	$12K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	219	$12K
10061		<1%	107	$12K
82010		<1%	1,478	$12K
86920		<1%	413	$12K
90686		<1%	1,272	$11K
72040		<1%	246	$11K
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	3,181	$11K
J3480	Injection, potassium chloride, per 2 meq	<1%	3,288	$11K
82247		<1%	1,842	$11K
86803		<1%	1,312	$11K
J7050	Infusion, normal saline solution, 250 cc	<1%	4,168	$11K
76819	Fetal biophysical profile; without non-stress testing	<1%	96	$10K
73140		<1%	179	$9K
87507		<1%	44	$9K
J0595	Injection, butorphanol tartrate, 1 mg	<1%	1,228	$9K
J1980	Injection, hyoscyamine sulfate, up to 0.25 mg	<1%	343	$9K
29581		<1%	497	$9K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	644	$8K
A0433	Advanced life support, level 2 (als 2)	<1%	104	$8K
97162		<1%	1,065	$8K
J2270	Injection, morphine sulfate, up to 10 mg	<1%	3,524	$8K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	2,178	$8K
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	2,808	$8K
76000		<1%	453	$8K
86592		<1%	1,997	$8K
J7042	5% dextrose/normal saline (500 ml = 1 unit)	<1%	1,853	$8K
95811		<1%	13	$7K
72072		<1%	143	$7K
82570		<1%	1,631	$7K
82248		<1%	1,533	$7K
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	8,837	$7K
94644		<1%	686	$6K
84550		<1%	1,418	$6K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	5,274	$6K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	72	$6K
84481		<1%	369	$6K
97116		<1%	1,307	$5K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	769	$5K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	67	$5K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	139	$5K
86038		<1%	496	$5K
G0410	Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes	<1%	122	$5K
97535	Self-care/home management training, each 15 minutes	<1%	1,484	$5K
J2795	Injection, ropivacaine hydrochloride, 1 mg	<1%	648	$5K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	51	$5K
G0283	Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care	<1%	1,255	$5K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	5,189	$5K
87340		<1%	603	$5K
J2060	Injection, lorazepam, 2 mg	<1%	1,971	$5K
84156		<1%	852	$5K
J2550	Injection, promethazine hcl, up to 50 mg	<1%	3,153	$5K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	685	$5K
36430		<1%	338	$5K
J1815	Injection, insulin, per 5 units	<1%	4,472	$4K
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	<1%	362	$4K
90688		<1%	412	$4K
73560		<1%	142	$4K
J1644	Injection, heparin sodium, per 1000 units	<1%	6,456	$4K
73552		<1%	96	$4K
J0461	Injection, atropine sulfate, 0.01 mg	<1%	626	$4K
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	359	$4K
80164		<1%	376	$4K
J1741	Injection, ibuprofen, 100 mg	<1%	1,844	$4K
82272		<1%	1,091	$4K
86308		<1%	314	$4K
84403		<1%	143	$4K
87641		<1%	415	$4K
S0077	Injection, clindamycin phosphate, 300 mg	<1%	317	$3K
71250		<1%	29	$3K
84100		<1%	3,088	$3K
J1756	Injection, iron sucrose, 1 mg	<1%	111	$3K
70498		<1%	41	$3K
70496		<1%	28	$3K
82565		<1%	1,274	$3K
95816		<1%	26	$3K
J0171	Injection, adrenalin, epinephrine, 0.1 mg	<1%	558	$3K
J1940	Injection, furosemide, up to 20 mg	<1%	4,040	$3K
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	940	$3K
94668		<1%	159	$3K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	20	$2K
72081		<1%	28	$2K
97598		<1%	16	$2K
80069		<1%	557	$2K
D7140	Extraction, erupted tooth or exposed root	<1%	13	$2K
77062		<1%	196	$2K
APT11		<1%	223	$2K
D2392	Resin-based composite - two surfaces, posterior, primary or permanent	<1%	14	$2K
74420		<1%	13	$2K
J3360	Injection, diazepam, up to 5 mg	<1%	352	$2K
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens	<1%	244	$2K
85018		<1%	1,436	$2K
83615		<1%	1,036	$2K
82950		<1%	414	$2K
87486		<1%	87	$2K
86762		<1%	245	$2K
87581		<1%	87	$2K
D2331		<1%	15	$2K
APT10		<1%	207	$2K
87210		<1%	265	$2K
72131		<1%	14	$2K
87147		<1%	311	$2K
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	<1%	271	$2K
73060		<1%	39	$2K
J2370	Injection, phenylephrine hcl, up to 1 ml	<1%	1,492	$2K
29505		<1%	92	$2K
J2919	Injection, methylprednisolone sodium succinate, 5 mg	<1%	355	$2K
G0257	Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility	<1%	222	$2K
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	<1%	248	$2K
29125		<1%	59	$2K
A9585	Injection, gadobutrol, 0.1 ml	<1%	172	$2K
J2360	Injection, orphenadrine citrate, up to 60 mg	<1%	312	$2K
77065	Tomosynthesis, mammo	<1%	95	$2K
J3490	Unclassified drugs	<1%	3,536	$2K
70491		<1%	12	$1K
C8930	Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision	<1%	34	$1K
91322		<1%	12	$1K
17250		<1%	72	$1K
D2934		<1%	13	$1K
90656		<1%	80	$1K
64450		<1%	26	$1K
82140		<1%	244	$1K
85014		<1%	880	$1K
11721		<1%	233	$1K
93308		<1%	19	$1K
J2543	Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)	<1%	294	$1K
97165		<1%	247	$1K
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	934	$1K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	56	$989.89
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	<1%	30	$976.94
90732		<1%	12	$954.00
J0736	Injection, clindamycin phosphate, 300 mg	<1%	215	$933.55
73070		<1%	31	$885.14
10060		<1%	25	$846.33
85049		<1%	531	$802.81
C9113	Injection, pantoprazole sodium, per vial	<1%	1,277	$781.11
94729		<1%	13	$777.19
Q3014	Telehealth originating site facility fee	<1%	67	$722.31
82105		<1%	127	$720.13
88313		<1%	25	$708.97
83655		<1%	88	$701.20
71271		<1%	12	$701.03
97150	Therapeutic procedure(s), group (2 or more individuals)	<1%	3,646	$684.41
11720		<1%	47	$672.06
87899		<1%	56	$644.22
86376		<1%	54	$638.98
82330		<1%	157	$638.82
84132		<1%	379	$606.76
J0330	Injection, succinylcholine chloride, up to 20 mg	<1%	111	$585.91
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	425	$585.37
84402		<1%	25	$574.36
88342		<1%	29	$567.92
A6210	Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing	<1%	1,663	$556.26
J3370	Injection, vancomycin hcl, 500 mg	<1%	145	$543.73
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	<1%	15	$521.03
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	<1%	189	$512.83
S0166	Injection, olanzapine, 2.5 mg	<1%	23	$512.28
88312		<1%	15	$503.41
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	<1%	582	$479.35
90670		<1%	104	$475.22
A9502	Technetium tc-99m tetrofosmin, diagnostic, per study dose	<1%	121	$472.50
96401		<1%	53	$471.20
82962		<1%	205	$459.96
85045		<1%	160	$447.83
J0780	Injection, prochlorperazine, up to 10 mg	<1%	204	$438.34
A6252	Specialty absorptive dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., without adhesive border, each dressing	<1%	1,201	$402.38
87046		<1%	63	$400.92
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	55	$396.61
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	12	$386.40
83986		<1%	81	$367.46
84436		<1%	103	$362.41
86923		<1%	38	$361.25
90480		<1%	12	$358.00
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	413	$340.73
P9612	Catheterization for collection of specimen, single patient, all places of service	<1%	103	$328.78
87045		<1%	61	$320.29
J3475	Injection, magnesium sulfate, per 500 mg	<1%	233	$313.78
J1920	Injection, labetalol hydrochloride, 5 mg	<1%	232	$312.97
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	13	$306.51
86696		<1%	12	$296.00
87209		<1%	16	$276.08
J1956	Injection, levofloxacin, 250 mg	<1%	43	$269.02
87425		<1%	16	$268.13
Q9969	Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose	<1%	491	$257.19
86431		<1%	29	$250.29
92610		<1%	13	$245.64
83525		<1%	27	$240.71
80347		<1%	17	$227.07
J1010	Injection, methylprednisolone acetate, 1 mg	<1%	27	$226.16
29105		<1%	12	$212.68
11056		<1%	14	$209.14
86695		<1%	12	$208.29
APT09		<1%	15	$178.65
J1596	Injection, glycopyrrolate, 0.1 mg	<1%	239	$177.41
90662		<1%	25	$164.24
81050		<1%	41	$155.63
J1953	Injection, levetiracetam, 10 mg	<1%	17	$152.79
99406		<1%	81	$145.97
J2470	Injection, pantoprazole sodium, 40 mg	<1%	203	$140.60
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	<1%	47	$135.59
87015		<1%	45	$133.41
87449		<1%	17	$133.11
J1171	Injection, hydromorphone, 0.1 mg	<1%	139	$130.65
87427		<1%	17	$122.45
J1642	Injection, heparin sodium, (heparin lock flush), per 10 units	<1%	675	$113.76
3044F		<1%	91	$113.17
87177		<1%	16	$109.25
84520		<1%	49	$94.13
J8499	Prescription drug, oral, non chemotherapeutic, nos	<1%	89	$92.86
51702		<1%	17	$86.23
96160		<1%	131	$77.16
84466		<1%	17	$76.11
80178		<1%	15	$74.47
J0688	Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg	<1%	80	$71.25
97166		<1%	27	$70.70
82465		<1%	13	$69.30
J3105	Injection, terbutaline sulfate, up to 1 mg	<1%	16	$53.07
82977		<1%	14	$52.62
84460		<1%	13	$49.77
97164		<1%	15	$47.16
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	<1%	43	$45.65
87493		<1%	15	$42.48
J2300	Injection, nalbuphine hydrochloride, per 10 mg	<1%	19	$38.85
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	<1%	64	$36.58
J0456	Injection, azithromycin, 500 mg	<1%	38	$34.25
84295		<1%	18	$31.88
99173		<1%	79	$30.60
90658		<1%	16	$26.12
J1630	Injection, haloperidol, up to 5 mg	<1%	24	$24.35
92551		<1%	59	$22.07
Q0247	Injection, sotrovimab, 500 mg	<1%	26	$17.20
70544		<1%	19	$16.97
G0008	Administration of influenza virus vaccine	<1%	550	$11.74
96127		<1%	17	$8.56
Q0244	Injection, casirivimab and imdevimab, 1200 mg	<1%	177	$7.85
36416		<1%	14	$5.36
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	101	$4.74
96161		<1%	17	$2.86
Q0222	Injection, bebtelovimab, 175 mg	<1%	33	$1.12
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	209	$0.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	0%	208	$0.00
G1004	Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program	0%	1,061	$0.00
90633		0%	14	$0.00
G8985	Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	27	$0.00
64447		0%	13	$0.00
G8984	Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals	0%	28	$0.00
80354		0%	17	$0.00
80348		0%	17	$0.00
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	0%	15	$0.00
90734		0%	14	$0.00
A9270	Non-covered item or service	0%	17,862	$0.00
90651		0%	25	$0.00
90620		0%	17	$0.00
99495		0%	13	$0.00
G8510	Screening for depression is documented as negative, a follow-up plan is not required	0%	12	$0.00
G8981	Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals	0%	14	$0.00
G8982	Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	0%	15	$0.00
90647		0%	26	$0.00
80050	General health panel	0%	30	$0.00
90723		0%	29	$0.00
41899	Unlisted procedure, dentoalveolar structures	0%	12	$0.00
C1769	Guide wire	0%	13	$0.00
87640		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGORMAN, MATTHEW (VP OF CORPORATE AND NETWORK SERVICE)

Same official

Other billing entities under GORMAN, MATTHEW

Full network →

Provider	Location	Paid
Floyd Physicians, LLC	Rome, GA	$2.64M
Floyd Healthcare Management INC	Rome, GA	$1.26M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.